A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people

2025-525025-12-00 Protocol Petadeferitrin-BA-01 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 10 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol Petadeferitrin-BA-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 18
Countries 1
Sites 1

Iron overload from thalassemia, transfusion-dependent myelodysplastic syndromea and haemolysis

Key facts

Sponsor
Pharmacosmos A/S
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
10 Apr 2026 → ongoing
Decision date (initial)
2026-04-07
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2025-525025-12-00
WHO UTN
U1111-1310-4466

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Iron overload from thalassemia, transfusion-dependent myelodysplastic syndromea and haemolysis

VersionLevelCodeTermSystem organ class
20.1 LLT 10054660 Thalassemia beta 10010331

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharmacosmos A/S

Sponsor organisation
Pharmacosmos A/S
Address
Roervangsvej 30
City
Holbaek
Postcode
4300
Country
Denmark

Scientific contact point

Organisation
Pharmacosmos A/S
Contact name
Lars Lykke Thomsen

Public contact point

Organisation
Pharmacosmos A/S
Contact name
Amalie Bjerre Jørgensen

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 18 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-04-10 2026-04-22

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-02-24 Netherlands Acceptable
2026-04-07
2026-04-07
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-22 Netherlands Acceptable
2026-04-07
2026-04-22
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-05-07 Netherlands Acceptable
2026-04-07
2026-05-07